As of June 9, 2025, Gilead Sciences Inc (GILD) reports a Net Margin of 1.67%.
Net Margin shows the share of revenue that becomes profit after all costs, reflecting overall profitability.
Historical Trend of Gilead Sciences Inc's Net Margin
Over recent years, Gilead Sciences Inc's Net Margin has shown significant volatility. The table below summarizes the historical values:
| Date | Net Margin |
|---|---|
| 2024-12-31 | 1.67% |
| 2023-12-31 | 20.89% |
| 2022-12-31 | 16.83% |
| 2021-12-31 | 22.80% |
| 2020-12-31 | 0.50% |
This slight downward trend highlights how Gilead Sciences Inc manages its overall profitability and cost control over time.
Comparing Gilead Sciences Inc's Net Margin to Peers
To better understand Gilead Sciences Inc's position, it's useful to compare its Net Margin against industry peers. Below are selected comparisons:
| Company | Net Margin |
|---|---|
| Gilead Sciences Inc (GILD) | 1.67% |
| Halozyme Therapeutics Inc (HALO) | 43.74% |
| United Therapeutics Corp (UTHR) | 41.53% |
| Regeneron Pharmaceuticals Inc (REGN) | 31.07% |
| CureVac NV (CVAC) | 30.30% |
| Alkermes Plc (ALKS) | 23.56% |
Compared to its competitors, Gilead Sciences Inc's Net Margin is about average compared to peers, reflecting typical industry profitability.